Insilico's AI drug Rentosertib shows 3-4 year biological age reversal in 12 weeks
NinaDSchick · x · 2026-09-08
- Insilico Medicine's AI-developed drug Rentosertib, now in Phase 3 trials, reportedly reversed biological aging: after 12 weeks of treatment, six independent aging clocks all showed participants measuring 3-4 years younger biologically.
- The paper's senior author calls it the most important publication of his career, presenting it first at Nature AI Healthcare in Paris, with broader implications for clinical trial design.
- If it holds up, this is a landmark for both AI drug discovery and the aging field.
Related event: AI-Designed IPF Drug Rentosertib Shows Biological Age Reversal in Trial(18 posts)→
More from AGI Musings
- GiveDirectly pilots an optional AI chatbot alongside cash aid in Rwanda — NathanpmYoung · 2026-10-27
- Ex-Anthropic employee essay: the org optimizes for power 'constrained by being seen as the good guys' — RichardMCNgo · 2026-10-27
- Investor: model version numbers are a mirage, only datacenter margins are real — StewartalsopIII · 2026-10-27
- WSJ Op-Ed: For Anthropic Share Offering Investors, a 10% Extinction Chance May Be a 90% Portfolio Win — davidmanheim · 2026-10-27
- WSJ: for Anthropic investors, a 10% extinction chance may still be a 90% portfolio win — peterwildeford · 2026-10-27
- Simile, the AI human-simulation startup, raises $300M+ at $2B valuation with 85%+ behavior prediction — joon_s_pk · 2026-10-27